However, TIDE failed to predict response to immunotherapy in HCC (P = .7), as shown in Figure 5D. We then evaluated whether the potential HCC groups were significantly changed in response to CTLA4 and PD1 inhibitor treatment, and the results showed that the high-risk group was likely to respond to PD1 inhibitor treatment, as shown in Figure 5E, which was consistent with the results in Figure 5C. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.